JPWO2021020564A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021020564A5 JPWO2021020564A5 JP2021535464A JP2021535464A JPWO2021020564A5 JP WO2021020564 A5 JPWO2021020564 A5 JP WO2021020564A5 JP 2021535464 A JP2021535464 A JP 2021535464A JP 2021535464 A JP2021535464 A JP 2021535464A JP WO2021020564 A5 JPWO2021020564 A5 JP WO2021020564A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen receptor
- chimeric antigen
- ganglioside
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019142358 | 2019-08-01 | ||
| JP2019142358 | 2019-08-01 | ||
| PCT/JP2020/029446 WO2021020564A1 (ja) | 2019-08-01 | 2020-07-31 | Ｇｄ２結合性分子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2021020564A1 JPWO2021020564A1 (https=) | 2021-02-04 |
| JPWO2021020564A5 true JPWO2021020564A5 (https=) | 2022-06-01 |
| JP7505784B2 JP7505784B2 (ja) | 2024-06-25 |
Family
ID=74228907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021535464A Active JP7505784B2 (ja) | 2019-08-01 | 2020-07-31 | Ｇｄ２結合性分子 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220275104A1 (https=) |
| EP (1) | EP4008347B1 (https=) |
| JP (1) | JP7505784B2 (https=) |
| BR (1) | BR112022001649A2 (https=) |
| ES (1) | ES3031393T3 (https=) |
| WO (1) | WO2021020564A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021020559A1 (ja) * | 2019-08-01 | 2021-02-04 | 国立大学法人三重大学 | 抗原受容体 |
| WO2023081485A1 (en) | 2021-11-08 | 2023-05-11 | Pacific Biosciences Of California, Inc. | Stepwise sequencing of a polynucleotide with a homogenous reaction mixture |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102164962B (zh) | 2008-06-30 | 2014-05-28 | 诺福泰克公司 | 抗gd2抗体和方法及其相关应用 |
| EP3323830B1 (en) | 2010-06-19 | 2023-08-23 | Memorial Sloan-Kettering Cancer Center | Anti-gd2 antibodies |
| WO2012033885A1 (en) | 2010-09-08 | 2012-03-15 | Baylor College Of Medicine | Immunotherapy of cancer using genetically engineered gd2-specific t cells |
| WO2013189516A1 (en) | 2012-06-18 | 2013-12-27 | Apeiron Biologics Ag | Method for treating a gd2 positive cancer |
| GB201403972D0 (en) | 2014-03-06 | 2014-04-23 | Ucl Business Plc | Chimeric antigen receptor |
| WO2016134284A1 (en) * | 2015-02-19 | 2016-08-25 | University Of Florida Research Foundation, Inc. | Chimeric antigen receptors and uses thereof |
| AU2017302668B9 (en) | 2016-07-28 | 2023-06-22 | Novartis Ag | Combination therapies of chimeric antigen receptors and PD-1 inhibitors |
| US20200101108A1 (en) * | 2017-03-31 | 2020-04-02 | The Board Of Trustees Of The Le-Land Standford Junior University | Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling |
| CA3287539A1 (en) * | 2017-06-21 | 2026-03-02 | Icell Gene Therapeutics Llc | CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF |
| IT201800007601A1 (it) * | 2018-07-30 | 2020-01-30 | Rigenerand Srl | Metodo per la produzione di cellule bi-funzionali per il trattamento di tumori |
| AU2020291939A1 (en) | 2019-06-13 | 2021-12-02 | Allogene Therapeutics, Inc. | Anti-TALEN antibodies and uses thereof |
-
2020
- 2020-07-31 EP EP20845660.8A patent/EP4008347B1/en active Active
- 2020-07-31 WO PCT/JP2020/029446 patent/WO2021020564A1/ja not_active Ceased
- 2020-07-31 JP JP2021535464A patent/JP7505784B2/ja active Active
- 2020-07-31 ES ES20845660T patent/ES3031393T3/es active Active
- 2020-07-31 BR BR112022001649A patent/BR112022001649A2/pt unknown
- 2020-07-31 US US17/631,745 patent/US20220275104A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Silence et al. | ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade | |
| Sawada et al. | Human monoclonal antibodies to sialyl-Lewisa (CA19. 9) with potent CDC, ADCC, and antitumor activity | |
| JP2021506244A5 (https=) | ||
| JP2021534802A5 (https=) | ||
| JP2015163068A5 (https=) | ||
| JP2021522801A5 (https=) | ||
| JP2017513478A5 (https=) | ||
| JP2020501531A5 (https=) | ||
| JP2020527144A5 (https=) | ||
| JP2020517249A5 (https=) | ||
| CN111194323A (zh) | 多特异性抗体 | |
| JP2019513370A5 (https=) | ||
| JP2015533853A5 (https=) | ||
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| JP2009502171A5 (https=) | ||
| JP2017500057A5 (https=) | ||
| JP2019505564A5 (https=) | ||
| KR20170085531A (ko) | 항-cldn 키메라 항원 수용체 및 사용 방법 | |
| JP2014534242A5 (https=) | ||
| KR20140018837A (ko) | 노텀 단백질 조절 인자 및 사용 방법 | |
| JP2013527762A5 (https=) | ||
| JPWO2021020564A5 (https=) | ||
| JP2020534012A5 (https=) | ||
| CN112292399A (zh) | 抗cd27抗体及其用途 | |
| JP2023530037A5 (https=) |